Soren E. Skovlund
Global Senior Project Manager, Global Market Access, former Director, global DAWN studies
In 2001, patient studies were showing that although highly effective treatments were on the market, over 50% of patients were failing to hit wellness indicators that showed they were in control of their condition.
Skovlund led a team to uncover why, and launched a huge patient survey to engage 5,426 diabetes patients, 2,194 primary care physicians, 556 specialists and 1,122 nurses across 13 countries.
Although the survey improved debate on gaps in service provision for patients, a retrospective study in 2011 showed that little had changed in key wellness indicators. Under Skovlund’s leadership, the company doubled down and launched an even bigger study.
Skovlund built on the first approach to involve patients in every step of the process, even study design. He also created a clearer strategy for impact, involving partners that could convert knowledge into change in treatment guidelines from day one. The results have been huge. The team uncovered a range of critical gaps in treatment, as well as shedding light on the burden on family members of diabetes patients for the first time. The recommendations have also been adopted at the highest level, with policy change in Denmark, Algeria, China and US to date.